Rani Therapeutics Holdings, Inc. (RANI) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Rani Therapeutics Holdings, Inc. (RANI) closed at USD 0.67 on 2026-10-14, a change of -64.6 % over the past year, with a market capitalization of USD 95.55M.

Rani Therapeutics Holdings, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Rani Therapeutics Holdings, Inc. key figures

Previous close

USD 0.67 (2026-10-14)

1-year change

-64.6 %

Market cap

USD 95.55M

Enterprise value

USD 37.4M

P/E ratio (trailing)

-4.53

P/E ratio (forward)

-3.58

EPS (trailing)

-0.15

EPS (forward)

-0.19

PEG ratio

n/a

Price to book

1.95

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

13.12

Employees

69

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans; and has a research and development collaboration with PegBio Co., Ltd. to expand obesity pipeline across multiple novel candidates. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Rani Therapeutics Holdings, Inc. and compare it with other stocks.